Upload
Featured Recent Articles Topics Login Upload

Search Results for 'patients ldl'

patients ldl published presentations and documents on DocSlides.

PCSK9 Inhibition: LDL Lowering
PCSK9 Inhibition: LDL Lowering
by SweetiePie
PCSK9 inhibitors. New option for dyslipidemia. Ali...
LDL is causal of atherosclerosis
LDL is causal of atherosclerosis
by morgan
Evidence from . meta-analyses of . Mendelian. . r...
LDL Apheresis in Drug Resistant Nephrotic Syndrome
LDL Apheresis in Drug Resistant Nephrotic Syndrome
by obrien
Rodney D Gilbert. Patient JM. 14 year old girl, pr...
Non-obese rheumatoid arthritis patients
Non-obese rheumatoid arthritis patients
by valerie
withlow. low-density lipoprotein have higher coro...
Hypertension & Cholesterol
Hypertension & Cholesterol
by cheryl-pisano
Blake Wachter, MD, PhD. Idaho Heart Institute. Ep...
Familial Hypercholesterolemia
Familial Hypercholesterolemia
by faustina-dinatale
KEY POINTS . FH is an autosomal dominant genetic...
Novel therapies for the prevention of atherosclerotic vascu
Novel therapies for the prevention of atherosclerotic vascu
by debby-jeon
Prof. . John . Kastelein. Academic Medical Centre...
협심증 ( 狹心症 )
협심증 ( 狹心症 )
by lois-ondreau
Kyung Woo Park, MD, PhD, MBA . Seoul National Uni...
FOURIER F urther cardiovascular
FOURIER F urther cardiovascular
by trish-goza
OU. tcomes. . R. esearch with PCSK9 . I. nhibiti...
Trial Design Evolocumab SC
Trial Design Evolocumab SC
by danika-pritchard
140 mg Q2W or 420 mg QM. Placebo SC. Q2W or QM. L...
LSU Journal Club Efficacy and Safety of
LSU Journal Club Efficacy and Safety of
by trish-goza
Evolocumab. in. Reducing Lipids and Cardiovascul...
PCSK-9 Inhibitors Paul J
PCSK-9 Inhibitors Paul J
by tatyana-admore
PCSK-9 Inhibitors Paul J Kovack , DO, FACC, FACO...
LDL Cholesterol Lowering with
LDL Cholesterol Lowering with
by shoffer
Evolocumab. and Outcomes in Patients with . Perip...
The case for intensive lipid management:
The case for intensive lipid management:
by SillyGoose
The opportunities and issues for cardiologists. Pr...
THE MANAGEMENT OF DYSLIPIDEMIA Updated Version 20 150 2006
THE MANAGEMENT OF DYSLIPIDEMIA Updated Version 20 150 2006
by ariel
VA/DoD Clinical Practice Guideline Introduction ...
CLEVELAND CLINIC JOURNAL OF MEDICINE VOLUME 73 NUMBER 1 J
CLEVELAND CLINIC JOURNAL OF MEDICINE VOLUME 73 NUMBER 1 J
by iris
CHRISTOPHER SIBLEY,MDDepartment of Cardiology,John...
Protecting the heart and the kidney:
Protecting the heart and the kidney:
by pressio
Implications from the SHARP trial. Dr. Christina R...
The State of
The State of
by olivia-moreira
Dyslipidemia. . Treatment. USA-145-101385. © . ...
DIABETES AND LIPID
DIABETES AND LIPID
by yoshiko-marsland
S-KHALILZADEH. Lipids are hydrophobic molecules t...
Protecting the heart and the kidney:
Protecting the heart and the kidney:
by marina-yarberry
Implications from the SHARP trial. Dr. Christina ...
Update: Lipid Guidelines
Update: Lipid Guidelines
by yoshiko-marsland
DO NOT BURN THE COOKIES. Amy R. Woods, M.D.. a. ...
Cholesterol-Lowering Drugs
Cholesterol-Lowering Drugs
by cheryl-pisano
Victor Nadler. Objectives. By the end of this cla...
The Importance of Potential
The Importance of Potential
by pamella-moone
Statin. in High Risk Patient. Masrul Syafri. Bag...
Management of Common Comorbidities in Diabetes
Management of Common Comorbidities in Diabetes
by celsa-spraggs
1. Obesity. Management of Common Comorbidities in...
Rational Order of Laboratory Tests in Cardiovascular Diseases
Rational Order of Laboratory Tests in Cardiovascular Diseases
by carneos
Sedighe. . S. adat . Ghorashi. . MD. Family Medic...
The New Cholesterol Guidelines:
The New Cholesterol Guidelines:
by lily
Beauty is in the Eye of the Beholder. Brian Asbill...
DYSLIPIDEMIA IN DIABETES
DYSLIPIDEMIA IN DIABETES
by esther
MAHTAB NIROOMAND M.D.. Assistant professor of End...
Drugs of hyperlipidemia
Drugs of hyperlipidemia
by eve
. 4. th. Stage . Dr. Dalia . Abd. Al- Kader. PhD...
D yslipidemia DR,DUAA HIASAT
D yslipidemia DR,DUAA HIASAT
by mackenzie
Objectives :.  Know the clinical terminology for ...
Diabetic dyslipidemia : The pro-
Diabetic dyslipidemia : The pro-
by deborah
atherogenic. role of CETP and future use of CETP ...
In The Name Of God Dyslipidemia
In The Name Of God Dyslipidemia
by PinkPandaBear
/Lipid management in . Diabetes. Dr.Zahra. . davo...
The role of cholesteryl ester transfer protein TaqIB polymorphism in y
The role of cholesteryl ester transfer protein TaqIB polymorphism in y
by sophie
Bilal Ilanbey Meral Kayikcioglu Ebru Demirel Sez...
Management of Dyslipidaemia
Management of Dyslipidaemia
by anderson
July 2017 Edition of Clinical Practice Guidelines ...
CLINICAL PRACTICE
CLINICAL PRACTICE
by mia
USTRALIAN FAMILY Vol. 37, No. 7, July 2008 ichard ...
Putting Your Skills to the Test
Putting Your Skills to the Test
by deborah
Which ONE of the following statements regarding th...
Hypolipidemic drugs Shaymaa F. Abbas
Hypolipidemic drugs Shaymaa F. Abbas
by norah
Pharmacology Department. 24 SLIDES. 1. Learning ob...
D yslipidemia Objectives :
D yslipidemia Objectives :
by arya
 Know the clinical terminology for . dyslipidemia...
Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes?
Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes?
by yoshiko-marsland
The REAL-CAD Study in 13,054 Patients . With Stab...
Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes?
Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes?
by luanne-stotts
The REAL-CAD Study in 13,054 Patients . With Stab...
It’s Complicated: Methods
It’s Complicated: Methods
by sherrill-nordquist
to assess medication nonadherence . and regimen c...